Advertisement

Chromatographia

, Volume 47, Issue 5–6, pp 264–270 | Cite as

The application of high performance liquid chromatography, coupled to nuclear magnetic resonance spectroscopy and mass spectrometry (HPLC-NMR-MS), to the characterisation of ibuprofen metabolites from human urine

  • E. Clayton
  • S. Taylor
  • B. Wright
  • I. D. Wilson
Originals

Summary

The use of HPLC-NMR-MS for the detection and identification of the metabolites of ibuprofen present in a solid phase extract of human urine is described. Gradient reversed-phase HPLC was used to separate the components present in the extract, which were then characterised by a combination of stopped-flow1H NMR and on line electrospray-MS. This approach led to the rapid identification of the known phase 1 human metabolites of ibuprofen, including hydroxy- and carboxy- metabolites, together with their respective glucuronide conjugates. In addition a probable artefact resulting from the dehydration of one of the side chainhydroxylated glucuronides was also identified.

Key Words

Column liquid chromatography NMR and MS detection Ibuprofen metabolites Urine extracts 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    K. Albert, E. Bayer in G. Patonay (editor), HPLC Detection: Newer Methods VCH, Weinheim, 1992, p. 369.Google Scholar
  2. [2]
    J. C. Lindon, J. K. Nicholson, U. G. Sidelmann, I. D. Wilson, Drug Metabolism Rev.29, 705 (1997).CrossRefGoogle Scholar
  3. [3]
    J. C. Lindon, J. K. Nicholson, I. D. Wilson, Advances in Chromatogr.36, 315 (1996).Google Scholar
  4. [4]
    F. S. Pullen, A. G. Swanson, M. J. Newman, D. S. Richards, Rapid. Comm. Mass Spectrom.9, 1003 (1995).CrossRefGoogle Scholar
  5. [5]
    J. S. Schockor, S. E. Unger, I. D. Wilson, P. J. D. Foxall, J. K. Nicholson, J. C. Lindon, Anal. Chem.68, 4431 (1996).CrossRefGoogle Scholar
  6. [6]
    K. I. Burton, J. R. Everett, M. J. Newmann, F. S. Pullen, D. S. Richards, A. G. Swanson, J. Pharm. Biomed. Anal.15, 1903 (1997).CrossRefGoogle Scholar
  7. [7]
    G. Scarfe, I. D. Wilson, M. Spraul, M. Hofmann, U. Braumann, J. C. Lindon, J. K. Nicholson, Anal. Comm.34, 37 (1997).CrossRefGoogle Scholar
  8. [8]
    R. M. Holt, M. J. Newman, F. S. Pullen, D. S. Richards, A. G. Swanson, J. Mass Spectrom.32, 64 (1997).CrossRefGoogle Scholar
  9. [9]
    G. B. Scarfe, B. Wright, E. Clayton, S. Taylor, I. D. Wilson, J. C. Lindon, J. K. Nicholson, Xenobiotica, in press.Google Scholar
  10. [10]
    S. Taylor, E. Clayton, B. Wirght, I. D. Wilson, in preparation.Google Scholar
  11. [11]
    M. Spraul, M. Hofmann, P. Dvortsak, J. K. Nicholson, I. D. Wilson, Anal Chem65, 327 (1993).CrossRefGoogle Scholar

Copyright information

© Friedr. Vieweg & Sohn Verlagsgesellschaft mbH 1998

Authors and Affiliations

  • E. Clayton
    • 1
  • S. Taylor
    • 1
  • B. Wright
    • 1
  • I. D. Wilson
    • 1
  1. 1.Zeneca Pharmaceuticals, MeresideMacclesfieldUK

Personalised recommendations